Premium
Clinical and prognostic features of patients with philadelphia chromosome‐positive chronic myelogenous leukemia and extramedullary disease
Author(s) -
Terjanian Terenig,
Kantarjian Hagop,
Keating Michael,
Talpaz Moshe,
McCredie Kenneth,
Freireich Emil J.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870115)59:2<297::aid-cncr2820590221>3.0.co;2-b
Subject(s) - medicine , chronic myelogenous leukemia , philadelphia chromosome , disease , leukemia , oncology , dermatology , genetics , chromosomal translocation , gene , biology
Twenty‐four patients who developed extramedullary disease during the course of Philadelphia chromosomepositive chronic myelogenous leukemia are described. The most frequent sites of extramedullary disease were lymph nodes (54%), bone (37%), and skin and soft tissue (29%). The appearance of extramedullary disease was associated with a high incidence of other features of accelerated disease (37%) and with cytogenetic clonal evolution (62.5%). The median time from extramedullary disease to blastic crisis was 4 months, and the median survival was 5 months. At the time of analysis, 23 patients have died, 16 after evolving into blastic crisis, and 7 from progressive disease without satisfying the criteria of medullary blastic crisis. This study confirms the importance of extramedullary disease as a sign of poor prognosis in chronic myelogenous leukemia, and the need for alternate therapies when such an event develops. Cancer 59:297–300, 1987.